WT1 Measurable Residual Disease Assay in Patients With Acute Myeloid Leukemia Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation: Optimal Time Points, Thresholds, and Candidates
2019 ◽
Vol 25
(10)
◽
pp. 1925-1932
◽
2021 ◽
Vol 27
(3)
◽
pp. S130-S131
2016 ◽
Vol 58
(5)
◽
pp. 1135-1143
◽
2018 ◽
Vol 23
(11)
◽
pp. 1349-1357
◽
2011 ◽
Vol 18
(6)
◽
pp. 381-387
◽
2020 ◽
Vol 155
(2)
◽